Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
clinical trial, phase IV
anticoagulants
haemorrhage
off-label use
stroke
thromboembolism
Journal
Acta cardiologica
ISSN: 1784-973X
Titre abrégé: Acta Cardiol
Pays: England
ID NLM: 0370570
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
8
1
2021
medline:
6
11
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC). Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation. NCT02944019; Date of registration: October 24, 2016.
Sections du résumé
BACKGROUND
BACKGROUND
Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.
METHODS
METHODS
With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC).
RESULTS
RESULTS
Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA
CONCLUSION
CONCLUSIONS
There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.
TRIAL REGISTRATION
BACKGROUND
NCT02944019; Date of registration: October 24, 2016.
Identifiants
pubmed: 33406996
doi: 10.1080/00015385.2020.1746095
doi:
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Pyridines
0
Thiazoles
0
edoxaban
NDU3J18APO
Banques de données
ClinicalTrials.gov
['NCT02944019']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM